Immuron Ltd key statistics and ratios

In fiscal 2026, Immuron Ltd had return on equity of -38.4%, an operating margin of -49.9%, debt equal to 0.0% of equity and a current ratio of 7.26. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Immuron Ltd: financial ratios, annual
Fiscal year	2016Jun 2016	2017Jun 2017	2018Jun 2018	2019Jun 2019	2020Jun 2020	2021Jun 2021	2022Jun 2022	2023Jun 2023	2024Jun 2024	2025Jun 2025	2026Jun 2026
Gross margin	69.9%	75.8%	97.8%	85.3%	72.6%	65.0%	68.4%	72.5%	68.1%	65.4%	64.5%
Operating margin	—	−481.5%	−209.0%	−231.0%	−115.4%	<−999%	−375.0%	−197.8%	−118.3%	−73.3%	−49.9%
Net margin	−706.1%	−487.3%	−210.6%	−231.0%	−116.2%	<−999%	−373.0%	−209.8%	−141.5%	−71.6%	−47.7%
Free-cash-flow margin	−515.5%	−497.6%	−241.0%	−89.3%	−125.0%	<−999%	−412.7%	−144.2%	−119.9%	—	−42.3%
Return on equity	—	−101.7%	−42.1%	−58.5%	−43.4%	−53.8%	−11.7%	−17.5%	−42.2%	−49.0%	−38.4%
Return on assets	−78.5%	−79.5%	−36.0%	−51.9%	−38.2%	−51.0%	−11.1%	−16.0%	−36.3%	−39.7%	−31.7%
Asset turnover	0.11	0.16	0.17	0.22	0.33	0.01	0.03	0.08	0.26	0.55	0.67
Current ratio	—	4.83	8.78	5.59	8.54	22.96	15.75	9.20	5.46	5.09	7.26
Debt to equity	—	2.1%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Interest cover (operating income ÷ interest)	—	—	—	—	n/m	n/m	n/m	n/m	n/m	—	—
R&D as % of revenue	362.0%	331.7%	154.9%	51.8%	46.8%	937.8%	86.0%	143.6%	109.6%	49.4%	25.1%
Capital spending as % of revenue	0.2%	0.4%	0.5%	0.1%	0.0%	4.5%	1.3%	0.4%	0.0%	—	0.1%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

2 of 2 checks passed · June 30, 2026

What it owns · $9m

Short-term assets $9mLonger-term assets $0m

What it owes, and who funded it · $9m

Short-term liabilities $1mLonger-term liabilities $0mShareholders' equity $8m

Short-term assets cover short-term liabilities $9m of assets due within a year against $1m of liabilities due within a year.
Short-term assets cover long-term liabilities $9m short-term assets against $139,093 of longer-dated liabilities.
More cash than debt Cash or debt not separately reported. Not assessable.
Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Immuron Ltd's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: IMRN vs IVA IMRN vs TSHA ANL vs IMRN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Immuron Ltd's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Immuron Ltd.